



Curriculum Vitae

Personal information **Ulla Wändel Liminga**

Work experience

1. Employer: Medical Products Agency
 - Start date: 011994
 - End date: 092007
 - Position: Non_clinical assessor
 - Activities:
 - Country: Sweden
2. Employer: European Medicines Agency
 - Start date: 041996
 - End date: 121997
 - Position: Scientific administrator
 - Activities:
 - Country: United Kingdom
3. Employer: Medical Products Agency
 - Start date: 102007
 - End date: 102008
 - Position: Acting Scientific Director Pharmacology/Toxicology
 - Activities:
 - Country: Sweden
4. Employer: Medical Products Agency
 - Start date: 112008
 - End date: 022020
 - Position: Scientific Director Pharmacology/Toxicology
 - Activities:
 - Country: Sweden
5. Employer: Medical Products Agency
 - Start date: 072012
 - End date: 062015
 - Position: PRAC alternate
 - Activities:
 - Country: Sweden
6. Employer: Medical Products Agency
 - Start date: 072015
 - End date:
 - Position: PRAC delegate
 - Activities:
 - Country: Sweden
7. Employer: Medical Products Agency
 - Start date: 032020
 - End date:
 - Position: Scientific director pharmacovigilance
 - Activities:
 - Country: Sweden

Education and training

1. Subject: Uppsala University, Faculty of Pharmacy
 - Start date: 011984
 - End date: 011988
 - Qualification: Master of Science in Pharmacy
 - Organisation:
 - Country: Sweden
2. Subject: Uppsala University, Faculty of Medicine
 - Start date: 011988
 - End date: 101993
 - Qualification: Doctor in Medical Sciences
 - Organisation:
 - Country: Sweden

Additional information

Publications

[Philipp Berg](#), [Charlotte Bakker](#), [Moritz Sander](#), [Nicklas Hasselblad Lundström](#), [Karin Erneholm](#), [Flora Musuamba Tshinanu](#), [Olga Kholmanshikh](#), [Filip Van Nuffel](#), [Susanne Müller](#), [Gabriele Ruppert-Seipp](#), [Gabriele D. Maurer](#), [Justina Januskiene](#), [Maria Mantziri](#), [Bianca Mulder](#), [Frederika A. van Nimwegen](#), [Dajana Vasilcanu](#) & [Ulla Wändel Liminga](#)

secondary malignancy of T-cell origin after CAR T-cell therapy; EMA's conclusions from the evaluation of 38 suspected cases. *Gene Ther* (2025). <https://doi.org/10.1038/s41434-025-00586-x>

Buoninfante, A., Andeweg, A., Baker, A.T., Mitesh Borad, Nigel Crawford, Jean-Michel Dogné, David Garcia-Azorin, Andreas Greinacher, Rita Helfand, Anders Hviid, Stefan Kochanek, Marta López-Fauqued, Ishac Nazy, Anand Padmanabhan, Sue Pavord, Daniel Prieto-Alhambra, Huyen Tran, Ulla Wandel Liminga and Marco Cavaleri Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination. *npj Vaccines* 7, 141 (2022) *npj Vaccines* (2022) 7:141 ; <https://doi.org/10.1038/s41541-022-00569-8>

van der Laan, J.W., Benson, C.T., Janssens, W. Bos J, Stahl E, Brady J.T., Wändel_Liminga U, Corriol_Rohou S, Forster R, Hartmann A, Pertel P.E., Robertson S.M., Silva_Lima B, Malik R.E., Chibout S.D. Shared Learnings on the New EMA First_in_Human and Early Clinical Trial Guideline: Proceedings From a DIAlogue Session at DIA Europe 2018. *Ther Innov Regul Sci* (2020) doi:10.1007/s43441_019_00077_3 *Läkartidningen* 2018;115:EZHR. R Ljung U. Wändel Liminga, R Gedeberg, E. Arlander. Alvedon 665 mg med modifierad frisättning på väg ut från marknaden. *Ceridono M, Tellner P, Bauer B, Barroso J, Alépée N, Corvi R, De Smedt A, Fellows M, Gibbs N, Heisler E, Jacobs A, Jirova D, Jones D, Kandárová H, Kasper D, Kinyamu Akunda J, Krul C, Learn D, Liebsch M, Lynch A, Muster W, Nakamura K, Nash JF, Pfannenbecker U, Phillips G, Robles C, Rogiers V, Van De Water F, Wändel Liminga U, Vohr HW, Watrelos O, Woods J, Zuang V, Kreysa J, Wilcox P. The 3T3 neutral red uptake phototoxicity test: Practical experience and implications for phototoxicity testing – The report of an ECVAM-EFPIA workshop August 2012 Regul Toxicol Pharmacol. 2012 Jun 9;63(3):480_488. [Epub ahead of print] Leconte I, Bailey G, Davis_Bruno K, Hew KW, Kim J, Silva Lima B, Liminga U, Moffit J, De Schaepe-drijver L, Schmitt G, Tassinari M, Thompson K, Hurtt M. Value of juvenile animal studies. *Birth Defects Res B Dev Reprod Toxicol.* 2011 Aug;92(4):292_303 Beyer BK, Chernoff N, Danielsson BR, Davis_Bruno K, Harrouk W, Hood RD, Janer G, Liminga UW, Kim JH, Rocca M, Rogers J, Scialli AR. ILSI/HESI maternal toxicity workshop summary: maternal toxicity and its impact on study design and data interpretation. *Birth Defects Res B Dev Reprod Toxicol.* 2011 Feb;92(1):36_51. Dencker L, Oskarsson A, Tegnell A, Liminga UW. [The level of mercury in Pandemrix is not associated with increased health risk]. [Article in Swedish] *Läkartidningen.* 2009 Dec 22;106(52):3522. Bremer S, Balduzzi D, Cortvrindt R, Daston G, Eletti B, Galli A, Huhtaniemi I, Laws S, Lazzari G, Liminga U, Smits J, Spano M, Themmen A, Tilloy A, Waalkens_Behrends I. The effects of chemicals on mammalian fertility. The report and recommendations of ECVAM Workshop 53the first strategic workshop of the EU ReProTect Project. *Altern Lab Anim.* 2005 Aug;33(4):391_416. Liminga U and Lima B. Non_clinical development of fixed combinations – A European Regulatory Perspective *Int J Pharm Med* 2004; 18 (3) Liminga U. Preclinical assessments of European Union marketing authorisation applications for immunomodulatory biopharmaceuticals. *Hum Exp Toxicol.* 2000 Apr;19(4):257_60. Liminga U, Andren PE, Öhlund LS, Gunne LM. High frequency oral movements induced by long_term administration of amperozide but not FG5803 in rats. *Psychopharmacology (Berl).* 1996 Feb;123(3):223_30. Ellison G, Liminga U, Keys A. Oral movement patterns induced in rats by local infusions into striatum depend upon the regimen of prior neuroleptic exposure. *Psychopharmacology (Berl).* 1995 Sep;121(2):259_66. Andrén PE, Levin ED, Liminga U, Gunne L. Behavioural and neurochemical consequences of ibotenic acid lesion in the subthalamic nucleus of the common marmoset. *Brain Res Bull.* 1995;36(3):301_7. Johnson AE, Liminga U, Lidén A, Lindefors N, Gunne LM, Wiesel FA. Chronic treatment with a classical neuroleptic alters excitatory amino acid and GABAergic neurotransmission in specific regions of the rat brain. *Neuroscience.* 1994 Dec;63(4):1003_20. Liminga U, Gunne LM. Intranigral stimulation of oral movements by [Pro9] substance P, a neurokinin_1 receptor agonist, is enhanced in chronically neuroleptic_treated rats. *Behav Brain Res.* 1993 Oct 21;57(1):93_9. Liminga U, Johnson AE, Andrén PE, Gunne LM. Modulation of oral movements by intranigral 5_hydroxytryptamine receptor agonists in the rat. *Pharmacol Biochem Behav.* 1993 Oct;46(2):427_33. Liminga U. Selective neurokinin NK1 and NK2 receptor agonists infused in the substantia nigra of the rat increase vacuous chewing. *Eur J Pharmacol.* 1993 Apr 28;235(2_3):177_81. Mitchell IJ, Crossman AR, Liminga U, Andren P, Gunne LM. Regional changes in 2_deoxyglucose uptake associated with neuroleptic_induced tardive dyskinesia in the Cebus monkey. *Mov Disord.* 1992;7(1):32_7. Liminga U, Johansson PE, Gunne L. Intranigral tachykinin NK3 receptor agonist elicits oral movements in rats. *Pharmacol Biochem Behav.* 1991 Mar;38(3):617_20. Maggio R, Liminga U, Gale K. Selective stimulation of kainate but not quisqualate or NMDA receptors in substantia nigra evokes limbic motor seizures. *Brain Res.* 1990 Oct 1;528(2):223_30. Liminga U, Johansson P, Nylander I, Gunne LM. Intranigral infusion of enkephalins elicits dyskinetic biting in rats. *Psychopharmacology (Berl).* 1989;99(3):299_303.*

[Projects](#)

[Memberships](#)

[Other Relevant Information](#)